According to Bloomberg, NewLimit, a longevity startup founded by Coinbase co-founder Brian Armstrong, has announced the completion of a $130 million Series B funding round, valuing the company at $810 million. This round was led by Kleiner Perkins, with other investors including Khosla Ventures and Human Capital. NewLimit aims to delay aging and restore cellular function by reprogramming specific proteins in human cells, having raised a total of $275 million to date, including $105 million from the founders at the company's inception in 2021 and $40 million in 2023.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
According to Bloomberg, NewLimit, a longevity startup founded by Coinbase co-founder Brian Armstrong, has announced the completion of a $130 million Series B funding round, valuing the company at $810 million. This round was led by Kleiner Perkins, with other investors including Khosla Ventures and Human Capital. NewLimit aims to delay aging and restore cellular function by reprogramming specific proteins in human cells, having raised a total of $275 million to date, including $105 million from the founders at the company's inception in 2021 and $40 million in 2023.